Introduction
============

Glaucoma is an eye disease characterized by optic atrophy and visual field defect. Primary glaucoma is divided into open-angle and angle-closure glaucoma. The incidence of glaucoma has been increasing with the development of science and technology and the overuse of eyes in recent years ([@b1-etm-0-0-8345],[@b2-etm-0-0-8345]). The disease has a very covert onset, so its pathogenesis remains unclear. Studies have shown that the onset is related to mechanical and vascular factors ([@b3-etm-0-0-8345]), so early diagnosis and timely treatment are crucial to prevent glaucoma patients from severe visual impairment ([@b4-etm-0-0-8345]).

Currently, glaucoma is mainly diagnosed by optic nerve examination and ultrasonic biomicroscopy. However, the two methods are expensive and susceptible to the subjective judgment of operators ([@b5-etm-0-0-8345]), which is not conducive to the diagnosis and the severity evaluation of the disease. Long non-coding RNA (lncRNA) is a long-chain non-coding RNA and its role in various diseases has been widely valued in recent years ([@b6-etm-0-0-8345]). lncRNA MALAT1, a typical and multifunctional non-coding RNA, has been reported to promote tumor metastasis by inducing epithelial-mesenchymal transformation ([@b7-etm-0-0-8345]).

According to a previous study, lncRNA MALAT1 plays a pivotal role in proliferative vitreoretinopathy, and affects apoptosis of retinal ganglion cells in glaucoma rats by regulating PI3K/Akt signaling pathway ([@b8-etm-0-0-8345]). As an lncRNA that has been widely studied, lncRNA ANRIL has been found to protect human trabecular meshwork cells of glaucoma mice by conditioning miR-7 ([@b9-etm-0-0-8345]). Although these studies have shown that lncRNA MALAT1 and lncRNA ANRIL play an important role in the development of glaucoma, their clinical value in glaucoma patients has been rarely analyzed.

Therefore, the expression of serum lncRNA MALAT1 and lncRNA ANRIL in glaucoma patients was detected to analyze their clinical significance in the patients, to provide more possibilities for the diagnosis and treatment of the disease.

Patients and methods
====================

### General information

Altogether 86 glaucoma patients diagnosed in the Hospital of Chengdu University of Traditional Chinese Medicine from January 2016 to June 2018 were enrolled (the study group), including 49 males and 37 females, with an average age of 51.19±1.33 years. A total of 86 people who underwent physical examinations and were confirmed to be healthy in the hospital during the same period were also enrolled (the control group). Inclusion criteria were as follows: patients diagnosed with glaucoma by optic nerve examination, ultrasound biomicroscopy, and visual field examination. Exclusion criteria were as follows: Patients complicated with other eye diseases; pregnant or lactating patients; patients complicated with other malignant tumor diseases; patients with severe diseases of the immune system; patients with severe hepatic and renal dysfunction. All patients and their families agreed to participate in the study, which was approved by the Hospital Ethics Committee.

### Detection of indices

Fasting venous blood (5 ml) was drawn from the patients in the morning of the next day after admission, anticoagulated with heparin, and centrifuged at 3,000 rpm for 5 min. The serum was taken out for the detection of the indices.

### qRT-PCR detection of lncRNA MALAT1 and lncRNA ANRIL

TRIzol reagent was used to extract total RNA from the serum, and an ultraviolet spectrophotometer was used to detect its purity and concentration. SYBR-Green Real-time PCR Master mix was used to reverse transcribe the total RNA of lncRNA MALAT1 and lncRNA ANRIL, with the steps carried out in strict accordance with the manufacturer\'s kit. Then, PCR amplification was carried out. The reaction conditions were: pre-degeneration at 95°C for 10 min, degeneration at 95°C for 15 sec, annealing at 60°C for 60 sec, and finally extension at 72°C for 30 sec, for 40 cycles. The primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd. GAPDH was used as an internal reference and 2^−ΔΔCt^ was used to calculate the relative expression ([Table I](#tI-etm-0-0-8345){ref-type="table"}).

### Detection of other relevant indices

The expression of serum pigment epithelium-derived factor (PEDF), homocysteine (Hcy), and inflammatory cytokines \[interleukin-12 (IL-12), interleukin-4 (IL-4) and interferon-γ (IFN-γ)\] was detected. Enzymatic cycling assay was used to determine the expression of serum Hcy. A fully automatic biochemical analyzer was used to analyze the expression of serum PEDF. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression of serum IL-12, IL-4 and IFN-γ.

### Statistical methods

In this study, SPSS 18.0 was used to statistically analyze the experimental data. A Chi-square test was used for count data. Measurement data were expressed as mean ± standard deviation. A t-test was used for comparison between two groups. Pearson was used for correlation analysis. Receiver operating characteristic (ROC) curves were plotted to analyze the diagnostic value of lncRNA MALAT1 alone, lncRNA ANRIL alone, and their combined detection for glaucoma. Multivariate Logistic regression was used for the multivariate analysis of risk factors for the disease. P\<0.05 indicates a statistically significant difference.

Results
=======

### Comparison of general information

There were no significant differences in sex, age, body mass index (BMI), and other information between the study and control groups (P\>0.05) ([Table II](#tII-etm-0-0-8345){ref-type="table"}).

### Comparison of expression of lncRNA MALAT1 and lncRNA ANRIL

The expression of serum lncRNA MALAT1 and lncRNA ANRIL in the study group was significantly lower than that in the control group (P\<0.05) ([Fig. 1](#f1-etm-0-0-8345){ref-type="fig"}).

### Comparison of other related indices

The expression of serum PEDF and IL-12 in the study group was significantly lower than that in the control group, while the expression of serum Hcy and IL-4 was significantly higher than that in the control group (P\<0.05), without significant difference in the expression of serum IFN-γ between the two groups (P\>0.05) ([Table III](#tIII-etm-0-0-8345){ref-type="table"}).

### Correlation of serum lncRNA MALAT1 and lncRNA ANRIL with PEDF, Hcy, IL-12 and IL-4

Serum lncRNA MALAT1 and lncRNA ANRIL were positively correlated with PEDF and IL-12 (P\<0.05), but negatively correlated with Hcy and IL-4 (P\<0.05) ([Table IV](#tIV-etm-0-0-8345){ref-type="table"} and [Fig. 2](#f2-etm-0-0-8345){ref-type="fig"}).

### Diagnostic value of lncRNA MALAT1 alone, lncRNA ANRIL alone, and their combined detection

The sensitivity, specificity, and area under the curve (AUC) of lncRNA MALAT1 for diagnosing glaucoma were 83.72, 66.28 and 0.836%, respectively. Those of lncRNA ANRIL were 81.40, 76.74 and 0.842%, respectively. With lncRNA MALAT1 and lncRNA ANRIL considered as independent variables, binary Logistic regression analysis was conducted, and a Logistic regression model: Logit (P)=0.884+1.673 lncRNA MALAT1+-2.960 lncRNA ANRIL was obtained. The sensitivity, specificity, and AUC of the model were 93.02, 79.07 and 0.932, respectively. The diagnostic value of the combined detection was higher than that of lncRNA MALAT1 alone and lncRNA ANRIL alone ([Fig. 3](#f3-etm-0-0-8345){ref-type="fig"}).

### Correlation of lncRNA MALAT1 and lncRNA ANRIL with clinicopathological features

The expression of lncRNA MALAT1 and lncRNA ANRIL was significantly related to the pathological staging of the patients (P\<0.05), but not to sex, age, BMI, types, and presence or absence of myopia (P\>0.05) ([Table V](#tV-etm-0-0-8345){ref-type="table"}).

Discussion
==========

Glaucoma is an eye disease that can lead to blindness. Intraocular hypertension causes damage to retinal ganglion cells, and then to vision and visual field, eventually resulting in glaucoma ([@b10-etm-0-0-8345],[@b11-etm-0-0-8345]). There are many theories about the pathogenesis of the disease, such as mechanical theory, vascular theory, and nervous activity theory. These theories believe that intraocular hypertension leads to apoptosis of retinal ganglion cells through different pathways ([@b12-etm-0-0-8345],[@b13-etm-0-0-8345]). LncRNA is a widely studied biomolecule. Its expression changes are closely related to the development and progression of many diseases, so it can be used as a molecular target for diagnosis or treatment ([@b14-etm-0-0-8345]).

lncRNA ANRIL regulates adjacent tumor suppressor gene CDKN2A/CDKN2B through an epigenetic mechanism and then regulates the proliferation and apoptosis of cells ([@b15-etm-0-0-8345]). According to a previous study exploring the mechanism of action of lncRNA ANRIL in glaucoma, lncRNA ANRIL reduces oxidative stress responses of human trabecular meshwork cells, thus inhibiting the pathogenesis of the disease ([@b15-etm-0-0-8345]). Previous studies have found that lncRNA MALAT1 plays a regulatory role in angiogenesis of endothelial cells ([@b16-etm-0-0-8345]), and inhibits apoptosis of neuronal cells by upregulating the expression of Bcl-2 ([@b17-etm-0-0-8345]). The clinical significance of lncRNA ANRIL and lncRNA MALAT1 in glaucoma was evaluated in our study. The two genes were poorly expressed in the serum of glaucoma patients. A previous study has shown that the downregulation of lncRNA MALAT1 expression leads to the decline of visual function and apoptosis of retinal cells, which also confirms the downregulation of lncRNA MALAT1 expression in patients with eye diseases ([@b18-etm-0-0-8345]), consistent with our findings.

Subsequently, the expression of serum Hcy, PEDF, IL-12, IL-4 and IFN-γ in the patients was detected to analyze the correlation of lncRNA ANRIL and lncRNA MALAT1 expression with glaucoma. The results showed that the expression of serum PEDF and IL-12 in the study group was significantly lower than that in the control group, while the expression of serum Hcy and IL-4 was significantly higher than that in the control group, without significant difference in the expression of serum IFN-γ between the two groups. Hcy, a sulfur-containing amino acid that is highly expressed in glaucoma patients, can damage vascular endothelial cells of eyes through multiple pathways, and induce optic atrophy ([@b19-etm-0-0-8345]). PEDF can be produced in many parts of the eyes inhibiting angiogenesis, so the reduction in its expression significantly increases the number of new vessels in the eyes, thus promoting the progression of glaucoma ([@b20-etm-0-0-8345]). IL-12 inhibits apoptosis of ganglion cells and then protects the optic nerve. IL-4 plays an important role during the process of optic nerve injury, and its high expression represents serious optic nerve injury ([@b21-etm-0-0-8345],[@b22-etm-0-0-8345]). These studies are consistent with our conclusions. The correlation of lncRNA ANRIL and lncRNA MALAT1 with Hcy, PEDF, IL-12 and IL-4 were analyzed. The results showed that serum lncRNA MALAT1 and lncRNA ANRIL were positively correlated with PEDF and IL-12, but negatively correlated with Hcy and IL-4, which further indicates that lncRNA MALAT1 and lncRNA ANRIL may be closely related to the progression of glaucoma.

The diagnostic value of lncRNA MALAT1 alone, lncRNA ANRIL alone, and their combined detection for glaucoma, and the correlation of the two genes with the clinicopathological features were analyzed. The results showed that the AUCs of lncRNA MALAT1 alone and lncRNA ANRIL alone were \>0.8, but the AUC of the combined detection was 0.93, which suggests that the latter has higher diagnostic value for glaucoma. According to the analysis of the clinicopathological features, the expression of lncRNA MALAT1 and lncRNA ANRIL was correlated with the pathological staging of glaucoma, which indicates that the low expression of the two genes represents serious glaucoma. This demonstrates that lncRNA MALAT1 and lncRNA ANRIL may be used as important markers for the severity evaluation of the disease. There are currently only few studies on this aspect, so more research is needed to confirm our conclusions.

In conclusion, lncRNA MALAT1 and lncRNA ANRIL are poorly expressed in the serum of glaucoma patients, significantly correlated with serum Hcy, PEDF, IL-12 and IL-4, and related to the pathological staging of the disease. Their combined detection has high diagnostic value for the disease. Therefore, lncRNA MALAT1 and lncRNA ANRIL may be used as new molecular targets for the diagnosis and severity evaluation of glaucoma patients. However, whether the two genes have a common mechanism of action in glaucoma is still unclear. Our conclusions should be further verified due to the few relevant studies and the small sample size in this study.
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###### 

Related primers.

  Factors   Upstream primers             Downstream primers
  --------- ---------------------------- ----------------------------
  MALAT1    5′-CAGTGGGGAACTCTGACTCG-3′   5′-GTGCCTGGTGCTCTCTTACC-3′
  ANRIL     5′-TGCTCTATCCGCCAATCAGG-3′   5′-GGGCCTCAGTGGCACATACC-3′
  GAPDH     5′-ACAGTCAGCCGCATCTTCTT-3′   5′-GACAAGCTTCCCGTTCTCAG-3′

###### 

General information.

  Factors                         Study group (n=86)   Control group (n=86)   t/χ^2^ value   P-value
  ------------------------------- -------------------- ---------------------- -------------- ---------
  Sex                                                                         0.024          0.878
    Male                          47 (54.65)           48 (55.81)                            
    Female                        39 (45.35)           38 (44.19)                            
  Age (years)                                                                 0.023          0.879
    ≤51                           41 (47.67)           42 (48.84)                            
    \>51                          45 (52.33)           44 (51.16)                            
  BMI (kg/m^2^)                                                               0.094          0.759
    ≤23                           40 (45.51)           38 (44.19)                            
    \>23                          46 (54.49)           48 (55.81)                            
  History of smoking                                                          0.223          0.637
    Yes                           31 (36.05)           34 (39.53)                            
    No                            55 (63.95)           52 (60.47)                            
  Educational background                                                      0.097          0.755
    Below junior high school      33 (38.37)           35 (40.70)                            
    Junior high school or above   53 (61.63)           51 (59.30)                            
  Place of residence                                                          0.216          0.642
    Countryside                   49 (56.98)           52 (60.47)                            
    City                          37 (43.02)           34 (39.53)                            
  Types                                                                       0.024          0.878
    Open-angle                    37 (43.02)           38 (44.19)                            
    Angle-closure                 49 (56.98)           48 (55.81)                            
  Creatinine (µmol/l)             62.77±4.24           63.05±4.31             0.668          0.430
  Blood urea nitrogen (mmol/l)      6.08±1.08            6.11±1.10                           

BMI, body mass index.

###### 

Detection of other related indices.

  Indices         Study group (n=86)   Control group (n=86)   t value   P-value
  --------------- -------------------- ---------------------- --------- ---------
  PEDF (pg/ml)    9.57±1.24            16.39±2.41             23.34     \<0.001
  Hcy (mmol/l)    18.52±2.96           5.79±1.36              36.24     \<0.001
  IL-12 (pg/ml)   93.24±12.83          138.55±18.28           18.81     \<0.001
  IL-4 (pg/ml)    258.41±31.58         182.49±24.96           17.49     \<0.001
  IFN-γ (pg/ml)   110.75±26.93         104.54±35.93           1.283     0.201

PEDF, pigment epithelium-derived factor; Hcy, homocysteine; IL, interleukin; IFN-γ, interferon-γ.

###### 

Correlation analysis.

          lncRNA MALAT1   lncRNA ANRIL            
  ------- --------------- -------------- -------- ----------
  PEDF    0.632           P\<0.001       0.606    P\<0.001
  Hcy     −0.686          P\<0.001       −0.911   P\<0.001
  IL-12   0.720           P\<0.001       0.717    P\<0.001
  IL-4    −0.633          P\<0.001       −0.650   P\<0.001

lncRNA, long non-coding RNA; PEDF, pigment epithelium-derived factor; Hcy, homocysteine; IL, interleukin.

###### 

Correlation of lncRNA MALAT1 and lncRNA ANRIL with clinicopathological features.

  Factors                  Relative expression of lncRNA MALAT1   t value   P-value   Relative expression of lncRNA ANRIL   t value   P-value
  ------------------------ -------------------------------------- --------- --------- ------------------------------------- --------- ---------
  Sex                                                                       0.674                                           0.464     0.644
    Male (n=47)            0.62±0.10                              0.422               0.63±0.09                                       
    Female (n=39)          0.61±0.12                                                  0.64±0.11                                       
  Age                                                             0.886                                                     0.879     0.382
    \<57 years (n=41)      0.65±0.09                                        0.388     0.67±0.12                                       
    ≥57 years (n=45)       0.63±0.12                                                  0.65±0.09                                       
  BMI                                                             1.316     0.192                                           0.422     0.675
    ≤23 (n=40)             0.67±0.10                                                  0.65±0.12                                       
    \>23 (n=46)            0.64±0.11                                                  0.66±0.10                                       
  Types                                                                     0.130                                                     0.124
    Angle-closure (n=37)   0.63±0.09                              1.530               0.61±0.10                             1.555     
    Open-angle (n=49)      0.66±0.09                                                  0.65±0.13                                       
  Myopia                                                          1.463     0.147                                           1.414     0.161
    Yes (n=52)             0.65±0.08                                                  0.64±0.10                                       
    No (n=34)              0.62±0.11                                                  0.67±0.09                                       
  Stages                                                                                                                              \<0.001
    I and II (n=47)        0.75±0.07                              18.28     \<0.001   0.74±0.08                             17.63     
    III and IV (n=39)      0.49±0.06                                                  0.48±0.05                                       

lncRNA, long non-coding RNA; BMI, body mass index.
